fda glp-1 enforcement news today FDA proposes a new GLP-1 compounding crackdown

Fmr. FDA Commissioner weighs in on Medicare's involvement in GLP-1 prices

25.57

★★★★☆4.8 (126)

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

24.98

★★★★★4.9 (98)

Report: FDA must enforce rules on compounded GLP-1s

28.55

★★★★★5.0 (157)

The New York Times spotlighted MEDVi. The FDA had already warned the self-proclaimed 'fastest growing company in history.'

27.70

★★★★★4.7 (84)

PCP PUBLIC HEALTH ADVISORY ON THE DANGERS OF COMPOUNDED AND NON-FDA APPROVED GLP-1 RECEPTOR AGONISTS

26.02

★★★★★4.9 (203)

Thinking about buying GLP-1 and other products labeled “for research purposes” or “not for human consumption”? Think again. These products have not been reviewed by FDA for safety, effectiveness or quality and

29.15

★★★★★5.0 (176)

🚨 Regulatory tightening is expanding beyond cannabinoids. With the FDA officially ending the GLP-1 shortage designation, the compounding loophole for certain peptide medications is closing triggering patent enforcement, compliance scrutiny, and market

23.93

★★★★★4.8 (132)